EFFECT OF TRIMETAZIDINE ON MYOCARDIAL KARYOMETRY DURING THE DOXORUBICIN-CYCLOPHOSPHAMIDE MODE OF CHEMOTHERAPY PRESCRIPTION
Main Article Content
Abstract
The subject of study. AC-mode of chemotherapy-induced cardiotoxicity, and rationality of trimetazidine prescription.
Purpose of the study – research the nuclear apparatus state of rats cardiomyocytes on chronic in vivo model of cancer therapy-driven cardiotoxicity, with a simultaneous assessment and justification for trimetazidine prescription.
Research methods. A fundamental, experimental, randomized, and controlled study was carried out. The object of the study was 120 male inbred Wistar rats. Chemotherapy was administered intraperitoneally. The introduction of trimetazidine - intragastrically. An Olympus IX51 microscope was used to assess the changes.
Main results. In 2th group on the background of the AC chemotherapy regimen, the value of the nuclear index was higher by 23.1 % and 24.2 % (p < 0.05) than in 1th and 4th groups. In 2th group on the background of AC chemotherapy, the value of the cross-sectional area of cardiomyocytes is higher by 33.3 % and 36.2 % (p < 0.05) than in 1th and 4th groups. In 3th group, against the background of trimetazidine, there is a statistically significant and clinically significant stabilization of the myocardial structure.
Application area. Pathological anatomy, cardiology.
Conclusions. Trimetazidine is a pathogenetically effective drug that prevent the cardiomyocytes from AC-mode of chemotherapy relared damaged.
Keywords
Article Details
Information about financing and conflict of interests
The author declares that there are no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N. Anthracycline Associated Disturbances of Cardiovascular Homeostasis. Curr Probl Cardiol. 2021. Article N: 100909. doi: 10.1016/j.cpcardiol.2021.100909
Avagimyan A, Kakturskiy L. The impact of trimetazidine on the anthropometric parameters of doxorubicin-cyclophosphamide mode in chemotherapy-induced heart alteration. Georgian Med News. 2022; (322): 158-161
Avagimyan AA, Mkrtchyan LH, Gevorkyan AA, Kononchuk NB, Kakturskiy LV, Djndoyan ZT. Relationship between chemotherapy and atrial fibrillation: clinical case. Rational Pharmacotherapy in Cardiology. 2021; 17(5): 785-791.https://doi.org/10.20996/1819-6446-2021-10-17
Avagimyan AA, Mkrtchyan LG, Kononchuk NB, Kaktursky LV, Agati L. Chemotherapy as a possible trigger for the myocardial lipomatosis development. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2021; 27(6): 706-712. https://doi.org/10.18705/1607-419X-2021-27-6-706-712
Bhagat A, Kleinerman ES. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv Exp Med Biol. 2020; 1257: 181-192. doi: 10.1007/978-3-030-43032-0_15
López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020; 41(18): 1720-1729. doi: 10.1093/eurheartj/ehaa006
Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020; 17(8): 474-502. doi: 10.1038/s41569-020-0348-1
Kolak A, Kamińska M, Sygit K, Budny A, Surdyka D, Kukiełka-Budny B, Burdan F. Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 2017; 24(4): 549-553. doi: 10.26444/aaem/75943
Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician. 2010; 81(11): 1339-1346
Hu C, Zhang X, Song P, Yuan YP, Kong CY, Wu HM, et al. Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway. Redox Biol. 2020; 37: 101747. doi: 10.1016/j.redox.2020.101747
Zhang YY, Yi M, Huang YP. Oxymatrine Ameliorates Doxorubicin-Induced Cardiotoxicity in Rats. Cell Physiol Biochem. 2017; 43(2): 626-635. doi: 10.1159/000480471
Wu YZ, Zhang L, Wu ZX, Shan TT, Xiong C. Berberine Ameliorates Doxorubicin-Induced Cardiotoxicity via a SIRT1/p66Shc-Mediated Pathway. Oxid Med Cell Longev. 2019; 2019: 2150394. doi: 10.1155/2019/2150394
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
https://www.ema.europa.eu/en/documents/product-information/savene-epar-product-information_en.pdf
Kochetkova I.V., Chernykh T.M., Panyushkina G.M. An experience of trimetazidine usage in comorbidity. Russian Journal of Cardiology. 2018;(3):37-42. Russian (Кочеткова И.В., Черных Т.М., Панюшкина Г.М. Опыт применения триметазидина у пациентов с коморбидной патологией //Российский кардиологический журнал. 2018. № 3. С. 37-42.) https://doi.org/10.15829/1560-4071-2018-3-37-42
Sheibani M, Nezamoleslami S, Faghir-Ghanesefat H, Emami AH, Dehpour AR. Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats. Cancer Chemother Pharmacol. 2020; 85(3): 563-571. doi: 10.1007/s00280-019-04019-6
Omole JG, Ayoka OA, Alabi QK, Adefisayo MA, Asafa MA, Olubunmi BO, Fadeyi BA. Protective Effect of Kolaviron on Cyclophosphamide-Induced Cardiac Toxicity in Rats. J Evid Based Integr Med. 2018; 23: 2156587218757649. doi: 10.1177/2156587218757649
Albengres E, Tillement J, Le Louet H, Morin D. Trimetazidine: Experimental and Clinical Update Review. Cardiovascular Drug Review. 2007; 16(4): 359-390